P3 Health Partners (NASDAQ:PIII) Full Year 2024 Results
Key Financial Results
- Revenue: US$1.50b (up 19% from FY 2023).
- Net loss: US$135.8m (loss widened by 135% from FY 2023).
- US$0.94 loss per share (further deteriorated from US$0.61 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
P3 Health Partners EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 67%.
Looking ahead, revenue is forecast to stay flat during the next 3 years compared to a 7.2% growth forecast for the Healthcare industry in the US.
Performance of the American Healthcare industry.
The company's shares are down 7.5% from a week ago.
Risk Analysis
Before we wrap up, we've discovered 3 warning signs for P3 Health Partners that you should be aware of.
Valuation is complex, but we're here to simplify it.
Discover if P3 Health Partners might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.